The World Health Organization (WHO) recommends weight band dosing of antiretrovirals for children. Data are limited describing drug exposure/safety of lopinavir/ritonavir using WHO weight band dosing. Methods: International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1083 was a phase II/III trial assessing the pharmacokinetics (PK) and short-term safety, tolerance and efficacy of lopinavir/ritonavir in human immunodeficiency virus-infected children 3-25 kg dosed according to WHO weight bands, with liquid solution or meltrex extrusion tablets. The main PK target was an area under the curve (AUC 0-24 ) of 80-320 μg·h/mL. Results: Of 97 enrolled participants, median age 2.5 years, 89 (91.8%) completed the protocol. Median LPV dose was 303 mg/m 2 . The geometric mean (90% confidence limits) LPV PK AUC 0-24 was 196 (177-217) μg·h/ mL and C min was 2.47 (1.52-4.02) μg/mL. AUC 0-24 was within the target range for 79% of participants. The median (Q1, Q3) difference between individual observed PK parameters and those expected if Food and Drug Administration dosing guidelines were followed was 30.7 (7.9, 54.3) for AUC 0-24 and 0.56 (0, 1.27) for C min . Ten (10%) participants had grade 3 or 4 events deemed related to study treatment, mostly asymptomatic laboratory abnormalities. Three participants died of unrelated study treatment causes. At week 24, 57 of 79 (72%) participants reached viral suppression and the median increase in CD4% (n = 83) was 6.0 (P < 0.0001). Conclusions: WHO weight band dosing guidelines in children achieved adequate LPV plasma exposure but was higher than that expected with Food and Drug Administration dosing guidelines. Despite the higher LPV exposure, the treatment was well tolerated and the 24-week efficacy data were favorable.
D espite significant progress in preventing new infant human immunodeficiency virus (HIV) infections and expanding antiretroviral treatment (ART) access to infected children, a large gap persists in many settings between actual and recommended universal ART for HIV-infected children. Although the World Health Organization (WHO) has recommended immediate initiation of antiretroviral (ARV) therapy for all children regardless of clinical or immunological status, almost half of children living with HIV are still not accessing these life-saving treatments. 1, 2 Since 2010, the WHO Pediatric ARV Working Group has recommended ARV dosing based on weight bands for use in resource-limited settings to simplify drug delivery and reduce prescription errors in children. 3 While the WHO ARV weight band dosing schedule for lopinavir/ritonavir (LPV/r) is now the standard dosing regimen used in most resource-limited settings, there are no data describing the plasma concentrations, safety profile or efficacy when LPV is dosed in infants and children following these recommendations. Additionally, genetic variation shown to affect the pharmacokinetics (PK) of LPV has not been evaluated in this population.
Data describing both the PK and clinical outcomes of LPV/r are crucial to evaluate the current WHO weight band dosing recommendations. The International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1083 study aimed to provide these data for LPV/r-naïve children as part of first-line therapy for children under age 3 years and as part of second-line therapy in older children who fail first-line therapy.
MATERIALS AND METHODS

Study Design and Participants
IMPAACT P1083 was a Phase II/III study to establish the PK, safety, tolerance and virologic effect of LPV/r when dosed according to the WHO ARV weight band dosing schedule in HIVinfected infants and children. This study was designed to determine the frequency of suboptimal LPV exposures. The goal was to describe the actual plasma concentrations of LPV achieved with this simplified dosing schedule and to determine whether the WHO ARV weight band dosing guidelines provide LPV exposure that is appropriate, safe, well-tolerated and virologically potent.
Eligibility criteria included LPV/r treatment naïve HIVinfected infants and children weighing ≥3 to <25 kg, with no planned concurrent use of non-nucleoside reverse transcriptase inhibitors, integrase inhibitors, entry inhibitors or protease inhibitors other than LPV/r. All participants' parents or legal guardians provided written informed consent.
Primary Outcome Measures
The main PK exposure parameter of interest was area under the curve (AUC) for lopinavir, as determined by a noncompartmental analysis of 12-hour PK sampling for LPV/r after 4 weeks of treatment. Because some participants took different morning and evening doses, estimated AUC 0-24 was used as the primary PK exposure parameter. The target range for the lopinavir AUC 0-24 was 80-320 μg·h/mL. Maximum and minimum concentrations (C max and C min ) were also calculated. In addition, the proportion of subjects with an AUC 0-24 of less than the 10th percentile of the mean expected for adults (AUC 0-24 <104 μg·h/mL) was calculated.
Participants met a safety endpoint if they experienced any grade 3 or higher toxicity judged by the team to be possibly, probably or definitely related to study drug.
Participants were considered to have not tolerated medication if they stopped treatment before the 24-week PK visit for any reason other than death/debilitation not related to treatment.
Secondary Outcome Measures
Adherence was measured by questionnaire and pill count or remaining volume of liquid drug at each visit while on treatment. The outcome measures for adherence were (1) reporting no missed doses and (2) the amount of medication taken as measured by the site divided by the amount expected with perfect adherence. The outcome measures for treatment efficacy were (1) having HIV RNA viral load <400 copies/mL at the week 24 visit and (2) having CD4% ≥25 at the week 24 visit.
Analytic Methods
Lopinavir was measured by the Pediatric Pharmacology Laboratory at University of California, San Diego and AMS-PHPT Pharmacology Laboratory at the Faculty of Associated Medical Sciences, Chiang Mai University, Thailand. Both laboratories utilized previously described, validated, reversed-phase multiplex high-performance liquid chromatography methods. 4, 5 Both laboratories participated in the DAIDS Clinical Pharmacology QA/QC program which includes proficiency testing for lopinavir in tests samples twice a year. At the University of California, San Diego Pediatric Pharmacology Laboratory, the lopinavir lower limit of quantification (LLOQ) was 0.091 μg/mL for with an interassay coefficient of variation (CV) ranged from 6.2% to 11% for the controls and an intra assay CV <4%. At the Chiang Mai Pharmacology Laboratory, the LLOQ was 0.078 μg/mL with intraand interassay CVs less than 4% for low, middle and high controls.
Clinical and Laboratory Monitoring
Clinical and laboratory events were classified according to the Division of AIDS 
Pharmacogenetic Analyses
Genetic polymorphisms in genes encoding for SCLO1B1, CYP3A4 and ORM1 were assessed. Specific single nucleotide polymorphisms evaluated were SLCO1B1 (rs4149056), SCLO1B1 (rs4149032), SCLO1B*1B (rs2306283), CYP3A4 (rs2740574), CYP3A4 (rs35599367), ORM1*F2 (rs1126801) and ORM1*S (rs14796186). Single nucleotide polymorphisms were detected by real-time polymerase chain reaction after extraction of DNA from dried blood spots (see Table, Supplemental Digital Content 1, http://links.lww.com/INF/C864 for specific primers and probes used to detect each of the single nucleotide polymorphisms).
Statistical Considerations
The target sample size of 85 participants was chosen to provide 90% confidence intervals (CIs), where the lower and upper limits would be within 10% of the true AUC for a variety of plausible AUC/CV combinations. It would also provide 80% power to detect the difference between a reference proportion of 25% of participants having AUC 0-12 <52, as found by Sáez-Llorens et al, 6 and a true proportion of 38%.
The PK analyses only included data from participants for whom all PK parameters were estimable; the remaining analyses included all participants. PK parameters were calculated using noncompartmental PK methods. The area under the plasma concentration-time curve (AUC 0-12 ) was estimated by the trapezoidal method over the dose interval (0-12 hours), maximum observed concentration of drug in plasma (C max ) and time of the maximum observed concentration in plasma (T max ) taken from observed concentrations. Apparent clearance (CL/F) was calculated as dose/ AUC 0-12 and normalized to body weight. Due to the relatively flat terminal portion of many of the concentration time profiles, plasma terminal half-life was not estimated. In 8 subjects, the sample scheduled to be collection 12 hours postdose deviated by more than 0.5 hours (all collected at 11 hours). For these subjects, the concentration at 12 hours (C 12 ) was estimated from the final 2 con- C . In addition, profiles were assessed for apparent steady-state conditions. Because at steady state, C 0 is approximately equal to C 12 , LPV concentration versus time profiles in which C 0 was within 4-fold of C 12 (0.25·C 12 < C 0 < 4·C 12 ) were deemed to meet the assumption of steady state. Profiles with C 0 to C 12 ratios outside the 0.25-4 range were designated "nonsteady state." In the setting with C 0 < 0.25·C 12 , AUC 0-∞ was estimated and used to determine CL/F using reverse-super positioning.
Because some WHO weight bands have different morning (dose . In instances where the morning dose and evening dose were the same, the AUC 0-24 was simply double the AUC 0-12 . A comparison of the observed exposure, based on WHO weight band dosing, and the expected exposure in these subjects with the Food and Drug Administration (FDA)-approved dose was performed. The AUC 0-24 and C min expected if FDA dosing guidelines were followed were estimated by multiplying the observed AUC 0-24 and C min by dose FDA /dose WHO . PK analysis was performed using WinNonlin ver 6.0 (Icon, Dublin).
Geometric means and associated 90% CIs were calculated for all PK parameters, overall and by weight/formulation strata. The proportion of participants with AUC 0-24 <104 μg·h/mL plus exact 90% binomial confidence limits (CLs) were calculated overall and by weight/formulation strata. The median difference between the actual AUC 0-24 and C min versus those expected if FDA dosing guidelines were followed was calculated overall and by weight/formulation strata.
Geometric means and associated 90% CLs of all PK parameters were also calculated for the genetic variants. Student's t test was used to compare PK parameters between the genetic variants by using the log-transformed values. Analyses for PK parameters used 90% CIs; all other analyses (safety, tolerability, etc) used 95% CIs. Within-participant changes in CD4% and viral load from entry to week 24 were examined using signed rank tests.
Study weeks for reporting of events (going off study or off treatment, adverse events) are calculated from the date of study enrollment. Results for 4-, 12-and 24-week visits are reported as of the dates those PK collections occurred.
All analyses except for the calculation of PK parameters were done using SAS 9.4.
RESULTS
Study Population
There were 97 participants enrolled from 19 sites in Brazil, Thailand, South Africa and the United States, of whom 57 participants received liquid formulation and 40 received 100/25 mg melt extrusion tablet formulation. The majority of participants (56%) were female. Forty percentage were Black, 38% Asian and 32% had Hispanic ethnicity. The median age at entry was 2.5 years, and ranged from 0.1 to 12.8 years. At study entry, the median HIV-1 RNA viral load was 5.2 log 10 copies/mL and the median CD4% was 24.2 (Table 1) .
Eighty-six (89%) participants completed study treatment. Three participants died, 2 from bacterial pneumonia and 1 from cardiomyopathy. Four subjects stopped the study drug, 1 because of a protocol-defined toxicity, 1 because of the need to take a disallowed medication and 2 because of drug intolerance. Four subjects left the study, 1 for noncompliance with the study regimen, 2 when parents/ guardians withdrew consent and 1 who was lost to follow-up.
PK of Lopinavir
There were 81 participants for whom all week 4 PK parameters could be estimated. In 8 subjects, the measured predose (C 0 ) was <0.25·C 12 strongly suggesting a missed prior dose. In half of these subjects, the C 0 was below the assay LLOQ and in the other half C 0 was greater than the LLOQ but less than 0.75 μg/mL and less than 15% of C 12 . In these subjects, AUC was calculated as AUC 0-∞ of the observed dose, where AUC 0-∞ = AUC C0-last + C last /λ z − C 0 /λ z. There were also 8 subjects with C 0 >4·C 12 , suggesting nonsteady-state conditions because of ingestion of an additional morning LPV/r dose before their intensive PK evaluations. Noncompartmental PK parameters could not be estimated from these profiles. There was also 1 subject with all LPV concentrations below LLOQ indicating nonadherence so that PK parameters could not be calculated.
Participants with and without complete week 4 PK data had similar characteristics, with the exception that those with missing PK data had lower viral loads at entry than those with complete data (median log 10 RNA 4.7 versus 5.2, Wilcoxon test P = 0.03).
The geometric mean and associated 90% CI for AUC 0-24 , C min and C max , both overall and by weight band/formulation are shown in Table 2 . The overall geometric mean AUC 0-24 (90% CI) was 196 (177-217). The target range for lopinavir AUC 0-24 was 80-320 μg·h/ mL. Sixty-four (79%) participants had week 4 AUC 0-24 in this range; 4 (5%) were below the target range and 13 (16%) were above it. Figure 1 shows dot plots of AUC 0-24 and C min by weight band and formulation. The 10-16.9 kg weight band had the highest proportion with AUC 0-24 above the target range, with more than a quarter exceeding 320 μg·h/ mL, while 100% of the 5-6.9 kg weight band were in the target range. The overall proportion of participants with AUC 0-24 below 104 μg·h/ mL and associated 90% exact CLs was 0.15 (0.09-0.23).
Solution Versus Melt Extrusion Formulation
Of the 81 subjects with full PK assessments, 46 (57%) received LPV/r as solution while 35 (43%) received tablets. The CL/F was higher in subjects receiving the liquid formulation than the tablet (0.179 versus 0.090 L/h/kg). Both AUC (195 versus 265 μg·h/mL) and C min (4.2 versus 6.5 μg/mL) were lower with the liquid formulation despite larger BSA-adjusted doses (331 versus 291 mg/m 2 ). However, achievement of target AUC exposure (80-320 μg·h/mL) was similar between the formulations-76% (liquid) versus 83% (tablet). Formulation and weight band were strongly confounded as the younger, lower weight participants all received the liquid formulation, making it impossible to determine if the differences in exposure were related to formulation versus age and weight. All 9 subjects that could not have AUC determined because of lack of steady-state conditions were receiving the liquid formulation, suggesting either less adherence or more erratic absorption in these younger subjects.
Comparison of WHO and FDA Dosing
The actual AUC 0-24 and C min of participants were compared with those expected if the FDA dosing guidelines were followed for each participant (Table 3) . Lopinavir exposures were higher with the WHO weight band doses. For the entire population combined, the increment with WHO weight band dosing compared with FDA dosing was 15.3% for AUC and 22.7% for C min .
Safety and Tolerance
Thirty-two (33%) participants had grade 3 or 4 events with a high proportion (14%) experiencing grade 3 or 4 serum amylase events. Ten (10%) participants had grade 3 or 4 events assessed by the team as Three participants died while on study. Two deaths were from bacterial pneumonia and 1 from cardiomyopathy, at study weeks 20, 26 and 4, respectively. All were assessed by the team as not related to study treatment.
Participants were considered to have not tolerated medication if they stopped treatment for any reason other than completing treatment or death/debilitation not related to treatment. Ninety (93%) participants tolerated treatment up to 24 weeks.
Adherence
Adherence questionnaires were administered at each PK visit. In the vast majority of cases at each time point, the primary caregiver was responsible for administering meds, either alone or shared with someone else. At the week 4 intensive PK visit, 89% reported no missed medication doses. By week 24, this had fallen to 77%. Across all 3 PK visits, there were 60 responses reporting problems giving LPV/r. The most frequent problems cited were "tastes bad" (n = 19), "refused to take" (n = 17), "forgot" (n = 15), "change in routine" (N = 9) and "child was ill" (N = 5). Five wrote that the child had trouble swallowing the tablet, felt nauseous or spit it out.
Adherence was also assessed by measuring the amount of medication used up (number of tablets or weight/volume of liquid) *The target range for LPV AUC 0-24 was 80-320 μg·h/mL based on studies establishing safety and efficacy of LPV/r. †Values of C min less than the lower limit of detection have been set to that limit (0.01 μg/mL) for the purpose of calculating the geometric mean. LCL indicates lower confidence limit; UCL, upper confidence limit. The WHO AUC 0-24 and C min represent the values observed in the current study with WHO weight band dosing. The FDA AUC 0-24 and C min values represent the expected values if these same subjects had received LPV/r using FDA recommended dosing. In subjects in whom the WHO and FDA recommend the same dose, the AUC and C min are identical and the differences is equals 0. Table 4 shows CD4% and HIV-1 RNA viral load for participants with data for both study entry (week 0) and week 24 visits. Median viral load at entry was 5.2 log 10 copies/mL and this significantly decreased (P < 0.001) to 1.9 log 10 copies/mL at week 24. At entry, all participants had viral loads >400 copies/mL, while 72% of subjects reached viral suppression (<400 copies/mL) at week 24. The median CD4% at entry was 24.1; at week 24 it was 29.5. CD4 percentages were significantly better at week 24, with the median change in CD4% 6.0, P < 0.0001. At entry, 46% of participants had CD4% ≥25; this rose to 71% at the week 24 visit.
Treatment Efficacy
Pharmacogenetics
Of the genetic variants evaluated, only the SLCO1B1 rs4149032 polymorphism was found to significantly affect lopinavir concentrations. As shown in Table 5 , subjects with a C allele (C/C + T/C) had a higher geometric mean AUC 0-24 compared with subjects homozygous for T/T (222.2 versus 160.9; P = 0.02, Figure 2 ). Consistent with the elevated AUC 0-24 , the geometric means of C min and C max were 72.6% and 26.4% higher in those carrying the C allele (P = 0.15 and P = 0.04, respectively). Similarly, as would be expected, the geometric mean CL/F was 27.8% lower in those children with the C allele compared with the T/T group (P = 0.03). Prevalence of C/C + T/C genetic variants was not affected by country of origin or ethnicity.
For the CYP3A4 rs2740574 polymorphism, subjects with the G allele compared with A/A homozygotes showed an increased mean CL/F of 30.7%, but geometric mean AUC 0-24 was only 7.7% lower and these findings were not statistically significant (P = 0.07 and P = 0.33, respectively). Similarly, subjects with a G allele had a mean C min 39% lower and a mean C C 12.5% lower when compared with A/A homozygotes (P = 0.15 and P = 0.24, respectively).
DISCUSSION
The WHO currently recommends a LPV/r-based regimen as the first-line treatment for HIV-infected children less than 3 years of age, and as the second-line for children older than 3 years failing an efavirenz-or nevirapine-based initial regimen. 1 Given the limited therapeutic options for infants and young children, it is critical to generate data informing exposure, safety and efficacy of LPV/r dosed according to WHO simplified weight band tables. This study demonstrates that children weighting 3-25 kg receiving LPV/r dosed according to the WHO weight band dosing recommendation achieve adequate plasma exposure. Seventy-nine percentage of children with full week 4 PK data met the target AUC 0-24 range (80-320 μg·h/mL), with only 4 (5%) below the target range and 13 (16%) above it. The overall geometric mean AUC 0-24 was 196 μg·h/ mL. Clinical outcomes were good, with 72% of participants achieving HIV-1 viral load <400 copies/mL and 71% achieving CD4% ≥25 at the week 24 visit.
By comparison, Sáez-Llorens et al 6 using the liquid LPV/r formulation achieved a mean AUC 0-12 of 72.6 using the FDAapproved LPV dose of 230 mg/m 2 , which is equivalent to an AUC 0-24 of 145.2, indicating that the WHO dosing recommendations are not leading to underdosing. Four (9%) participants on liquid formulation had AUC 0-24 below the target range. However, the AUC was similar for liquid and tablet in the overlap weight band 10-16.9 kg, suggesting that age rather than formulation was the cause for the lower AUCs. The increase in LPV apparent clearance (CL/F) observed at lower weight bands is consistent with what has been reported elsewhere. 7, 8 In the Children with HIV in Africa-Pharmacokinetics and Adherence of Simple Antiretroviral Regimens (CHAPAS-2) study trial, conducted in Ugandan children aged 3 months to 13 years, a novel generic minitab pellet formulation stored in capsules (40/10 mg LPV/r) was not bioequivalent to innovator solution (80/20 mg LPV/r) or generic tablet (100/25 mg LPV/r), with exposure with minitabs higher than with that solution and lower than that with tablets. Despite the high variability in PK parameters, subtherapeutic trough concentrations were rare and the minitabs were more acceptable than solution for children less than 4 years, mostly because of ease of transportation and storage, although taste remained a concern. 9 We also saw a difference in LPV/r PK in participants based on formulation. The liquid solution formulation overall achieved lower LPV concentrations than the tablet. Because the tablet formulation was only given to larger, older children weighing at least 10 kg, age and formulation findings are confounded. However, the 1 weight band that received both solution and tablet formulations, 10-16.9 kg, had similar PK results.
LPV/r treatment was generally safe and very well tolerated. Ten (10%) participants had grade 3 or 4 events assessed by the team as possibly, probably or definitely related to study treatment. Three participants died; all deaths were assessed by the team as not related to study treatment. Ninety (93%) participants tolerated treatment. Adherence was also good in our study population.
At the week 4 intensive PK visit, 89% reported no missed medication doses. By week 24, this had fallen to 77%.
The potential impact of pharmacogenomics on lopinavir PK was also explored. Genetic variants within the OATP/ SLCO family of polypeptide organic anion transporters have been associated with lopinavir PKs. Lopinavir and other HIV protease inhibitors are substrates for transporters SLCO1B1 and SLCO1A2, and the SLCO1B1 521-T/C genetic variant is associated with higher plasma levels of lopinavir in adults. [10] [11] [12] [13] We also saw a modest impact of this variant on lopinavir PK in children. While other polymorphisms in genes encoding for CYP3A4 and ORM1 have been implicated in altering the PK of protease inhibitors including lopinavir, 14, 15 we did not find a significant influence in the current study.
While the simplified WHO weight band dosing did result in higher exposures than would be expected with FDA dosing, the modest magnitude of difference and the lack of toxicity indicates the potential utility of this dosing strategy. A formulation specific dosing approach could be designed to achieve a higher percentage in the target range. However, the complexity of different doses based on formulation and the lack of toxicity seen with modestly higher AUCs supports the current unified dosing approach across formulations. In October 2014, UNAIDS: Joint United Nations Program on HIV/AIDS launched the "90:90:90" targets to help end the AIDS epidemic: by 2020, 90% of people living with HIV will be diagnosed, 90% of those diagnosed will be on sustained ART with 90% viral suppression in those on ART. 16 The greatest challenge in achieving these targets will be ensuring that their reach is extended to all populations. For the pediatric population, this will require providing treatment to 2.4 million HIV-infected infants, children and adolescents by 2020. 17 To achieve these ambitious targets and to reduce the high, early mortality of pediatric HIV, the development of easy to administer, solid, heat stable and affordable ARV formulations that are conformable to age and weight band dosing requirements is essential. Our findings demonstrate that LPV/r can be administered using weight band dosing to achieve safe and effective drug levels in HIV-infected children.
